| Pharmaceutical Information |
| Drug Name |
Pembrolizumab |
| Drug ID |
BADD_D01700 |
| Description |
Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing S228P Fc mutation.[A18829] It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds.[F136] It was developed by Merck & Co and firstly approved for the treatment of metastatic malignant melanoma. This is the first approved therapy against PD-1.[A7624] It was approved firstly by the FDA on September 4, 2014.[L2954] Its approval in melanoma was extended to several countries such as Australia, Israel, Korea, Macau, the European Union and the United Arab Emirates.[A33350] On June 12, 2018, Pembrolizumab was approved for the treatment of cervical cancer under the status of accelerated approval.[L2955] |
| Indications and Usage |
Pembrolizumab is indicated for the following conditions:[L38934] |
| Marketing Status |
approved |
| ATC Code |
L01FF02 |
| DrugBank ID |
DB09037
|
| KEGG ID |
D10574
|
| MeSH ID |
C582435
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
0006-3026; 69497-0001; 75895-0136; 83012-010 |
| UNII |
DPT0O3T46P
|
| Synonyms |
pembrolizumab | SCH-900475 | lambrolizumab | MK-3475 | Keytruda |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
1374853-91-4 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
